Anticavity Rinse

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the prevention of dental cavities in children aged 6 years and older. It aids in reducing the incidence of cavities, thereby promoting oral health in the targeted pediatric population.

Dosage and Administration

Adults and children aged 6 years and older should use the rinse once daily, following brushing with toothpaste.

To administer, the cap should be removed, and 10 milliliters (10 mL mark on the inside of the cap) should be poured, ensuring not to exceed the 10 mL mark. The individual should vigorously swish the 10 milliliters of rinse between their teeth for 1 minute before spitting it out. It is important to instruct patients not to swallow the rinse.

After rinsing, patients should refrain from eating or drinking for 30 minutes to allow optimal efficacy of the product. For children under 12 years of age, it is essential to instruct them in proper rinsing techniques to minimize the risk of swallowing. Supervision may be necessary until the child is capable of using the rinse without assistance. For children under 6 years of age, consultation with a dentist or doctor is recommended prior to use.

Contraindications

Use is contraindicated if more than the recommended amount for rinsing is accidentally swallowed. In such cases, seek professional assistance or contact a Poison Control Center immediately.

Warnings and Precautions

Healthcare professionals should be aware of the following warnings and precautions associated with the use of this product.

In the event that more than the recommended amount used for rinsing is accidentally ingested, it is imperative to seek professional assistance or contact a Poison Control Center immediately. This precaution is critical to ensure patient safety and to mitigate any potential adverse effects resulting from accidental ingestion.

While specific emergency medical interventions are not detailed, healthcare providers should remain vigilant and prepared to respond to any unforeseen complications that may arise during the use of this product.

Currently, there are no specified laboratory tests recommended for monitoring the safe use of this product. However, healthcare professionals should exercise clinical judgment and consider appropriate monitoring based on individual patient circumstances and any concurrent medications or conditions.

It is essential for healthcare providers to remain informed and proactive in managing the safety and efficacy of this product in their patients.

Side Effects

Patients receiving the treatment did not report any specific adverse reactions during clinical trials. Additionally, there were no warnings associated with the use of this medication. As such, the safety profile appears to be favorable based on the available data. Further monitoring and postmarketing experiences may provide additional insights into the long-term safety and tolerability of the treatment.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Anticavity Rinse (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be instructed to keep the product out of reach of children. In the event that more than the recommended amount for rinsing is accidentally swallowed, professional assistance should be sought or a Poison Control Center contacted immediately.

For children aged 6 years and older, the product is to be used once daily after brushing teeth with toothpaste. It is important to instruct children under 12 years of age in proper rinsing habits to minimize the risk of swallowing. Supervision is recommended for children until they are capable of using the product without assistance.

For children under 6 years of age, consultation with a dentist or doctor is advised prior to use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients may use this medication as no specific safety concerns regarding pregnancy have been detailed in the prescribing information. There are no dosage modifications recommended for pregnant individuals, nor are there any special precautions regarding its use during pregnancy. Healthcare professionals should continue to evaluate the benefits and risks when prescribing this medication to women of childbearing potential.

Lactation

Nursing mothers should consult a healthcare professional before using this product. There is a potential for excretion in breast milk; therefore, caution is advised when administering to nursing mothers. The effects on the nursing infant are not well studied; thus, the risks versus benefits should be considered.

Renal Impairment

Patients with renal impairment may require a reduced dose of the medication. Dosage adjustments should be based on creatinine clearance levels to ensure safety and efficacy. Regular renal function tests are recommended to monitor kidney health in patients receiving this medication. Additionally, special monitoring is necessary for patients with severe renal impairment to mitigate potential risks associated with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Monitoring of vital signs and laboratory parameters may be warranted to assess the patient's condition and guide further management.

Healthcare professionals should remain vigilant for potential symptoms that could indicate an overdosage scenario, although specific symptoms have not been detailed. If any concerning signs or symptoms develop, appropriate medical intervention should be sought immediately.

For further guidance, healthcare providers are encouraged to consult local poison control centers or relevant medical authorities to obtain the most current recommendations for managing suspected overdosage cases.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients that if more than the recommended amount used for rinsing is accidentally swallowed, it is crucial to seek professional assistance or contact a Poison Control Center immediately. This information is essential for ensuring patient safety and prompt action in case of accidental ingestion.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers assigned for identification. It is essential to store the product at room temperature to maintain its integrity and efficacy. No special handling requirements are necessary beyond standard storage practices.

Additional Clinical Information

The product is administered orally, with a recommended frequency of once daily after brushing teeth with toothpaste. Clinicians should instruct patients, particularly children under 12 years of age, on proper rinsing techniques to minimize swallowing. It is essential to supervise children until they are capable of using the product without assistance. Patients should be advised not to swallow the rinse and to refrain from eating or drinking for 30 minutes following the rinsing procedure.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Anticavity Rinse, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)